Myeloma Minute: A Darzalex Game Changer
![]() |
|
![]() |
FDA Approval of Darzalex in Early Relapse Setting a Game ChangerOn November 21st, Darzalex® (daratumumab) was approved by the US Food and Drug Administration in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone for the treatment of myeloma patients who have received at least one prior therapy. This represents a remarkably rapid extension of the initial label for use as monotherapy in the relapse/refractory setting granted in November 2015. Based upon the POLLUX (Rd) and CASTOR (Vd) datasets, there is now a new standard of care for patients at first relapse or even with inadequate initial response.
A new “backbone” agent is a real breakthrough and will transform the treatment landscape for the better. |
We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb